Novo Nordisk Balances Buybacks and Pipeline Bets as Shares Sit 25% Below Year-Start Levels

Novo Nordisk has spent DKK 10.25bn of its DKK 15bn buyback and signed a Nanexa licensing deal worth up to EUR 1.165bn as CagriSema trails Zepbound.

Novo Nordisk has been busy on two fronts at once: buying back its own equity at pace while simultaneously paying up for new drug technology. The Danish drugmaker's dual strategy comes as its stock trades well off its 52-week high, weighed down by pipeline setbacks and intensifying competition in the obesity market.

Buyback Program Nears Two-Thirds Completion

Under a repurchase plan authorized at up to DKK 15 billion, Novo Nordisk had accumulated 36,604,179 of its own B-shares by October 2, spending DKK 10,247,270,869 in the process. The program launched on February 4, 2026, and runs for twelve months, with the current sub-tranche extending through February 2027. Management's aim is straightforward: return excess cash to shareholders and give earnings per share a lift. With roughly two-thirds of the approved envelope already deployed, the company has moved quickly to put the capital to work.

Nanexa Licensing Deal Worth Up to EUR 1.165 Billion

Alongside those capital measures, Novo Nordisk has secured access to a new formulation platform. The company signed a licensing agreement with Nanexa covering its PharmaShell technology, with potential application across as many as five peptide drug development programs. The deal could ultimately be worth up to EUR 1.165 billion to Nanexa, comprising up to EUR 615 million in upfront, development, and regulatory milestone payments, plus a further EUR 550 million tied to future sales milestones and additional royalties.

The technology is designed to improve how peptide active ingredients are formulated and delivered. For Novo Nordisk, the platform opens additional avenues to refine existing drug approaches and shore up its product range through new dosage forms over the longer term.

Regulatory Snag on Denecimig, but Guidance Holds

Not everything has gone to plan. The FDA has extended its review of Denecimig, a hemophilia A treatment candidate submitted in September 2025, citing outstanding remediation work at a manufacturing facility. The agency did not provide a new decision date. Novo Nordisk stressed that no efficacy or safety deficiencies were identified and that its 2026 financial guidance remains intact. The company still targets a US market launch in the first half of 2027, subject to approval.

In Europe, the picture is brighter: the Committee for Medicinal Products for Human Use (CHMP) has already issued a positive recommendation, though the European Commission's formal decision is still pending. To sharpen its commercial positioning in rare diseases, Novo Nordisk is also studying patient preferences. A survey conducted in Germany is capturing the priorities of adult hemophilia patients regarding protection, safety, and the mode of administration for hypothetical preventive therapies — data intended to help refine the product profile against established standard treatments.

CagriSema Trails Zepbound, but CEO Points to 23% Weight Loss

Investor attention, however, remains fixed on the obesity franchise. The combination drug CagriSema produced somewhat less weight loss than Eli Lilly's rival Zepbound. CEO Mike Doustdar nonetheless highlighted a weight reduction of 23% achieved with the treatment. An FDA regulatory decision on CagriSema is expected by the end of 2026, while results from the follow-up REDEFINE 11 trial, involving 600 participants, are due in the first half of 2027.

Oral GLP-1 Rights Secured for Most of the World

Beyond the Nanexa tie-up, Novo Nordisk has locked in worldwide rights to the oral GLP-1/GIP candidate HRS-1596 outside mainland China, Hong Kong, Macau, and Taiwan. Subject to customary closing conditions, that transaction is slated to complete in the fourth quarter of 2026.

Analyst Stance Unchanged, Valuation Still Under Pressure

JPMorgan left its rating on the Danish stock at "Neutral" on Monday, according to media reports, with a price target held steady at DKK 275. The shares closed at EUR 33.13 in the prior session, down 25% since the start of the year and a long way from their 52-week high of EUR 54.86. With a market capitalization of EUR 146.96 billion, Novo Nordisk remains a sector heavyweight despite the recent headwinds. Whether the product launches slated for 2027 and upcoming trial readouts can restore momentum in the pipeline is the question the coming quarters will have to answer.